ASCO GU 2017: Phase II trial of TI-CE high dose chemotherapy (HDCT) with drug monitoring for individual carboplatin dosing in patients with relapsed advanced germ cell tumors: A multicenter prospective GETUG trial. - Session Highlights
Orlando, Florida USA (UroToday.com) At the genitourinary cancer symposium this year, Christine Chevreau presented the benefit of high dose chemotherapy using the TICE regimen with drug monitoring in patients with advanced germ cell tumors.
ASCO GU 2017: 111- A single-arm trial evaluating one cycle of BEP as adjuvant chemotherapy in high-risk, stage 1 non-seminomatous or combined germ cell tumors of the testis (NSGCTT). - Session Highlights
Orlando, Florida USA (UroToday.com) At this years genitourinary cancer symposium Robert Huddart presented the possibility of reducing chemotherapy burden to non-seminoma testis cancer without reducing oncologic efficacy. He presented that 1 cycle of bleomycin, etopiside and cisplatin (BEP) in high risk, stage 1 non-seminoma germ cell tumor (NSGCT) may be comparable to 2 cycles of BEP if a higher dose of etopiside is used.
ASCO GU 2017: Dacomitinib (Daco) induction therapy for locally advanced (LA) or metastatic penile squamous cell carcinoma (PSCC): An open label, single-arm, phase II study. - Session Highlights
Orlando, Florida USA (UroToday.com) Andrea Necchi presented an exciting abstract at this year’s genitourinary cancer symposium expanding targeted therapy with use of daconatinib to penile squamous cell carcinoma. Patients with advanced disease and significant burden generally do poor in penile cancer. Therefore there is a need for further investigation in this rare disease. Dacomatinib is an irreversible TKI of human EGFR/HER1, HER2 and HER4. Necchi presented a phase 2 study (NCT01728233) of daconatinib (45mg daily) on patients with squamous cell histology, and clinical stage N2-3 or M1 disease and have not received prior chemotherapy.
ASCO GU 2017: How best to treat locally advanced penile cancer: radiation versus surgery - Session Highlights
Orlando, Florida USA (UroToday.com) In this debate, the use of unimodal radiation therapy for T2 squamous cell carcinoma (SCC) was proposed. According to the NCCN guidelines, surgery is currently the gold standard for treatment of T2 penile SCC. As delineated by Dr. Vitaly Margulis from UT Southwestern, surgical excision provides excellent local control as well as specimen for detailed histologic analysis.
ASCO GU 2017: Orphan Cancers with Opportunities for Improved Treatment: Genomic profiling of penile squamous cell carcinoma reveals new opportunities for targeted therapy - Session Highlights
Orlando, Florida USA (UroToday.com) Dr. Scott Tomlins from the University of Michigan summarized the current understanding of the genomic landscape of penile squamous cell carcinoma (SCC).
ASCO GU 2017: Genetic Conditions With a Predisposition to Renal Cell Carcinoma - Session Highlights
Orlando, Florida USA (UroToday.com) Dr. W. Marston Linehan, Chief of the Urologic Oncology Branch at the National Cancer Institute, gave the keynote lecture in renal cell carcinoma (RCC). The focus of his talk was genetic conditions that predispose to RCC.
ASCO GU 2017: Con: Is There a Role for Treatment Intensification for Patients With Poor Prognosis Germ-Cell Tumors With Unfavorable Marker Decline? - Session Highlights
Orlando, Florida USA (UroToday.com) Dr. George Bosi noted that the standards of treatment for poor-risk nonseminomatous germ-cell tumors are either bleomycin, etoposide, and cisplatin or etoposide, ifosfamide, and cisplatin x 4, with overall survival (OS) at 5 years being 50%.